A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study of N91115 to Evaluate Safety and Pharmacokinetics in Patients with Cystic Fibrosis Homozygous for the F508del-CFTR Mutation
|Effective start/end date
|1/31/15 → 1/31/17
- NIVALIS THERAPEUTICS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.